Ionis Pharmaceuticals IONS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's operating income?
- Ionis Pharmaceuticals (IONS) reported operating income of -$117.42M in Q1 2026.
- How has Ionis Pharmaceuticals's operating income changed year-over-year?
- Ionis Pharmaceuticals's operating income increased by 20.0% year-over-year, from -$146.86M to -$117.42M.
- What is the long-term trend for Ionis Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's operating income has grown at a 88.6% compound annual growth rate (CAGR), from -$30.19M to -$381.69M.
- What does operating income mean?
- Profit generated from core business activities before interest and taxes.
- How do you interpret operating income?
- Positive and growing operating income indicates a healthy, self-sustaining business model.
- How does operating income compare across companies?
- Biotech companies often report negative operating income during high-investment clinical trial phases.